NASDAQ:MGEN - Miragen Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $21.50
  • Forecasted Upside: 38.49 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.46 (-2.88%)
Get New Miragen Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MGEN

Analyst Price Target is $21.50
▲ +38.49% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Miragen Therapeutics in the last 3 months. The average price target is $21.50, with a high forecast of $37.00 and a low forecast of $6.00. The average price target represents a 38.49% upside from the last price of $15.53.

This chart shows the closing price for MGEN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Miragen Therapeutics. This rating has held steady since July 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/31/2020OppenheimerReiterated RatingBuy$5.00 ➝ $37.00N/A
12/15/2020JMP SecuritiesInitiated CoverageOutperformLow
11/24/2020WedbushReiterated RatingOutperformLow
10/6/2020HC WainwrightDowngradeBuy ➝ NeutralHigh
8/17/2020WedbushReiterated RatingBuy$6.00High
8/10/2020Jefferies Financial GroupReiterated RatingBuyHigh
7/24/2020WedbushReiterated RatingBuy$6.00Low
7/21/2020Brookline Capital ManagementInitiated CoverageBuy$6.00High
6/23/2020WedbushReiterated RatingBuy$6.00Low
5/13/2020WedbushReiterated RatingBuy$6.00Medium
5/8/2020HC WainwrightReiterated RatingBuyMedium
3/12/2020WedbushReiterated RatingBuy$8.00High
1/30/2020WedbushReiterated RatingBuy$8.00 ➝ $10.00High
1/23/2020WedbushReiterated RatingBuy$8.00High
12/12/2019WedbushReiterated RatingPositive ➝ Buy$24.00 ➝ $8.00Low
12/12/2019Robert W. BairdDowngradeOutperform ➝ NeutralHigh
12/2/2019HC WainwrightReiterated RatingBuy$3.00High
8/19/2019HC WainwrightInitiated CoverageBuy$3.00High
5/21/2019WedbushReiterated RatingBuy$24.00Low
4/29/2019WedbushReiterated RatingOutperform$24.00High
3/18/2019WedbushReiterated RatingOutperform ➝ Outperform$22.00 ➝ $24.00High
1/4/2019Robert W. BairdInitiated CoverageOutperform ➝ OutperformHigh
12/31/2018B. RileyInitiated CoverageBuy ➝ Buy$18.50 ➝ $18.50High
10/8/2018WedbushReiterated RatingOutperform$19.00Medium
8/8/2018WedbushReiterated RatingBuy$19.00High
6/7/2018WedbushReiterated RatingBuyLow
5/18/2018WedbushReiterated RatingOutperform$19.00Low
4/30/2018WedbushReiterated RatingOutperform$19.00Low
4/9/2018CowenReiterated RatingHoldMedium
3/29/2018Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$14.00Medium
3/28/2018WedbushReiterated RatingOutperform$19.00Medium
3/22/2018Deutsche Bank AktiengesellschaftInitiated CoverageBuy$15.00Medium
3/20/2018WedbushReiterated RatingOutperformMedium
3/9/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$19.00Low
1/16/2018Chardan CapitalReiterated RatingBuyLow
1/12/2018OppenheimerInitiated CoverageOutperform$13.00High
1/5/2018B. RileyInitiated CoverageBuy ➝ Buy$15.50High
12/1/2017WedbushReiterated RatingBuy$19.00Low
10/16/2017Chardan CapitalReiterated RatingBuy$29.00N/A
8/18/2017WedbushReiterated RatingBuyLow
8/14/2017Chardan CapitalReiterated RatingBuy$26.00 ➝ $29.00High
8/7/2017Chardan CapitalReiterated RatingBuyHigh
7/25/2017Chardan CapitalReiterated RatingBuy$26.00High
6/1/2017CowenInitiated CoverageOutperformMedium
5/11/2017WedbushBoost Price TargetOutperform$16.00 ➝ $17.00Low
5/2/2017WedbushReiterated RatingOutperform$19.00Medium
4/3/2017WedbushReiterated RatingOutperform$19.00Low
2/23/2017WedbushReiterated RatingBuy$19.00N/A
2/21/2017WedbushInitiated CoverageOutperform ➝ OutperformN/A
8/21/2016Rodman & RenshawSet Price TargetBuy$4.00N/A
(Data available from 8/2/2016 forward)
Miragen Therapeutics logo
Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.
Read More

Today's Range

Now: $15.53
Low: $15.33
High: $16.19

50 Day Range

MA: $17.69
Low: $14.34
High: $23.01

52 Week Range

Now: $15.53
Low: $4.66
High: $34.05


4,762 shs

Average Volume

134,027 shs

Market Capitalization

$60.67 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Miragen Therapeutics?

The following Wall Street analysts have issued reports on Miragen Therapeutics in the last twelve months: HC Wainwright, Jefferies Financial Group Inc., JMP Securities, Oppenheimer Holdings Inc., Wedbush, and Zacks Investment Research.
View the latest analyst ratings for MGEN.

What is the current price target for Miragen Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Miragen Therapeutics in the last year. Their average twelve-month price target is $21.50, suggesting a possible upside of 38.5%. Oppenheimer Holdings Inc. has the highest price target set, predicting MGEN will reach $37.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $6.00 for Miragen Therapeutics in the next year.
View the latest price targets for MGEN.

What is the current consensus analyst rating for Miragen Therapeutics?

Miragen Therapeutics currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MGEN will outperform the market and that investors should add to their positions of Miragen Therapeutics.
View the latest ratings for MGEN.

What other companies compete with Miragen Therapeutics?

How do I contact Miragen Therapeutics' investor relations team?

Miragen Therapeutics' physical mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The medical research company's listed phone number is 720-643-5200 and its investor relations email address is [email protected] The official website for Miragen Therapeutics is